GSDMD-dependent IL-1 signaling in intestinal inflammation

肠道炎症中 GSDMD 依赖性 IL-1 信号传导

基本信息

  • 批准号:
    10024455
  • 负责人:
  • 金额:
    $ 54.17万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-24 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Abstract: About 1.3 million people suffer from IBD (chronic inflammation of the intestine) in the United States. The etiology of IBD remains elusive and preventive measures or a cure are not available. Inflammasomes and derived cytokines IL-1β are being intensely investigated as the signaling hub that is dys-regulated in inflammatory bowel disease (IBD). IL-1β is synthesized as inactive pro-forms with no secretory signal sequence. Recent studies have found that a lipid binding protein, Gasdermin D (GSDMD), is required for release of IL-1β in response to caspase-1/11 inflammasome activation. This breakthrough led to a rapid growth of literature that focuses on the pore forming and associated pyroptotic activity of GSDMD in myeloid cells. Interestingly, we discovered a novel nonpyrototic role of GSDMD in guiding the release of IL-1β containing vesicles from intestinal epithelia cells and T cells in response to Caspase 8 (Casp8) but not casp1 activation. Through unbiased proteomic analysis, we identified a set of novel GSDMD-interacting proteins in intestinal epithelial cells (IECs), including NEDD4 (an E3 ligase) and the Hsp90 co-chaperone CDC37. Ablation of GSDMD or NEDD4 abolished LPS and ATP-induced IL-1β production from IECs. Strikingly, LPS+ATP stimulation led to the polyubiquitination of pro-IL-1β, which was secreted and processed into mature IL-1β along with a complex containing full-length GSDMD, Hsp90/CDC37, NEDD4, Atg7, Casp8 but not Casp1. In vitro ubiquitination assay demonstrated that NEDD4, known to interact with LC3 and promote cargo loading into secretory vesicles, catalyzed the polyubiquitination of pro-IL-1β. Indeed, while GSDMD was associated with LC3+ vesicles; GSDMD-dependent release of extracellular vesicles (< 200 nm) were detected by electron microscopy, which contains the GSDMD/NEDD4/IL-1β complex. Moreover, inactivating mutation in the Asp276 of GSDMD, which abolishes its pore-forming and pyroptotic activity, did not impact the GSDMD-guided IL-1β secretion from IECs. In TH17 cells, a T helper cell subset highly relevant to intestinal inflammation, this GSDMD-guided secretion of polyubiquitinated pro-IL-1β complex (GSDMD, Hsp90, Casp8 and NEDD4) was also readily detected in response to ATP stimulation and TCR activation. Collectively, the data revealed a novel nonpyroptotic role for GSDMD in IL-1β release from non-myeloid cells. The pathogenic role of the GSDMD-guided IL-1β release was investigated in two mouse models of intestinal inflammation. Firstly, while polyubiquitinated pro-IL-1β, mIL-1β and the GSDMD/NEDD4-secretary complex were induced in a GSDMD-dependent manner in the intestinal explants in response to dextran sodium sulfate (DSS)-induce colitis, GSDMD-deficiency attenuated the intestinal inflammation. Secondly, GSDMD or IL-1β deficiency in naïve T cells reduced their ability to elicit intestinal inflammation. Based on these findings, we hypothesize that the GSDMD mediates distinct pathways (guided secretion and pyroptosis) for IL-1β release in non-myeloid and myeloid cells, which jointly contribute to the pathogenesis of intestinal inflammation in a coordinated manner. We will test this hypothesis through the following aims: (1) Investigate the molecular mechanism for GSDMD-guided secretory pathway for IL-1β release; (2) Investigate the cell-type and pathway-specific role of GSDMD-IL-1β axis in intestinal inflammation, including GSDMD-mediated pyroptotic versus GSDMD-guided IL-1β secretion on the intestinal inflammation.
抽象的: 在美国,大约有130万人患有IBD(肠道慢性感染)。病因 IBD仍然难以捉摸,预防措施或治疗不可用。炎症并得出 细胞因子IL-1β正在积极研究为炎症肠中调节的信号枢纽 疾病(IBD)。 IL-1β被合成为无秘书信号序列的非活性促成形式。最近的研究 已经发现,释放IL-1β的脂质结合蛋白Gasdermin d(GSDMD)响应于 caspase-1/11炎性体激活。这一突破导致文学的迅速增长,重点是 GSDMD在髓样细胞中的孔形成和相关的凋亡活性。有趣的是,我们发现了一本小说 GSDMD在指导含肠上皮细胞和含有IL-1β的蔬菜的非流动性作用 T细胞响应caspase 8(CASP8)而不是CASP1激活。通过公正的蛋白质组学分析,我们 确定了一组新型的GSDMD相互作用蛋白在肠上皮细胞(IEC)中,包括NEDD4(E3 连接酶)和HSP90副酮CDC37。 GSDMD或NEDD4消除了LPS和ATP诱导的 IEC的IL-1β产生。令人惊讶的是,LPS+ATP刺激导致了Pro-IL-1β的多泛素化,这是 分泌并加工成成熟的IL-1β,以及包含全长GSDMD的复合物,HSP90/CDC37, NEDD4,ATG7,CASP8,但不是CASP1。体外泛素化测定法证明了NEDD4,已知可以相互作用 使用LC3并促进货物加载到秘密蔬菜中,催化了Pro-IL-1β的多泛素化。的确, GSDMD与LC3+蔬菜有关; GSDMD依赖性细胞外蔬菜的释放(<200 通过含有GSDMD/NEDD4/IL-1β复合物的电子显微镜检测到NM)。而且, GSDMD的ASP276中的灭活突变,废除了其孔形成和凋亡活性 影响IEC的GSDMD引导的IL-1β分泌。在Th17细胞中,T辅助细胞子集与 肠炎,这种GSDMD引导的多泛素化pro-IL-1β复合物的分泌(GSDMD,HSP90, 还响应ATP刺激和TCR激活而容易检测到CASP8和NEDD4)。共同 该数据揭示了GSDMD在非乳突细胞中释放IL-1β中的新型非凋亡作用。致病性 在两种小鼠注射小鼠模型中,研究了GSDMD引导的IL-1β释放的作用。首先, 虽然在A中诱导了多泛素化的Pro-IL-1β,MIL-1β和GSDMD/NEDD4秘书络合物 肠外植物中的GSDMD依赖性方式响应硫酸葡萄糖钠(DSS)诱导的结肠炎, GSDMD缺陷减弱了肠道注射。其次,幼稚的T细胞中的GSDMD或IL-1β缺乏症 降低了他们引起肠道炎症的能力。基于这些发现,我们假设GSDMD 介导非肌动物和髓样细胞中的IL-1β释放的不同途径(引导秘密和凋亡), 这共同以协调的方式共同导致肠道炎症的发病机理。我们将测试这个 通过以下目的假设:(1)研究GSDMD引导分泌的分子机制 IL-1β释放的途径; (2)研究GSDMD-IL-1β轴在细胞类型和途径特异性的作用 肠炎,包括GSDMD介导的凋亡与GSDMD引导的IL-1β分泌 肠炎。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xiaoxia Li其他文献

Xiaoxia Li的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xiaoxia Li', 18)}}的其他基金

Core B: Animal Model and Immunotyping Core
核心 B:动物模型和免疫分型核心
  • 批准号:
    10493942
  • 财政年份:
    2022
  • 资助金额:
    $ 54.17万
  • 项目类别:
IL-17-driven mechanisms for tumor progression and resistance to therapies
IL-17 驱动的肿瘤进展和治疗耐药机制
  • 批准号:
    10493940
  • 财政年份:
    2022
  • 资助金额:
    $ 54.17万
  • 项目类别:
The role of TRAF4 E3 ligase in IL-25-mediated allergic asthma
TRAF4 E3 连接酶在 IL-25 介导的过敏性哮喘中的作用
  • 批准号:
    10112955
  • 财政年份:
    2020
  • 资助金额:
    $ 54.17万
  • 项目类别:
The role of TRAF4 E3 ligase in IL-25-mediated allergic asthma
TRAF4 E3 连接酶在 IL-25 介导的过敏性哮喘中的作用
  • 批准号:
    9885028
  • 财政年份:
    2020
  • 资助金额:
    $ 54.17万
  • 项目类别:
IRAKM and Mincle in ALD
IRAKM 和 Mincle 在 ALD 中
  • 批准号:
    9067893
  • 财政年份:
    2015
  • 资助金额:
    $ 54.17万
  • 项目类别:
IRAKM and Mincle in ALD
IRAKM 和 Mincle 在 ALD 中
  • 批准号:
    8912063
  • 财政年份:
    2015
  • 资助金额:
    $ 54.17万
  • 项目类别:
Myeloid cells, aging and the metabolic syndrome
骨髓细胞、衰老和代谢综合征
  • 批准号:
    8702069
  • 财政年份:
    2013
  • 资助金额:
    $ 54.17万
  • 项目类别:
Myeloid cells, aging and the metabolic syndrome
骨髓细胞、衰老和代谢综合征
  • 批准号:
    8611557
  • 财政年份:
    2013
  • 资助金额:
    $ 54.17万
  • 项目类别:
Molecular mechanisms of IL-1R-TLR mediated signaling
IL-1R-TLR介导信号传导的分子机制
  • 批准号:
    8242732
  • 财政年份:
    2011
  • 资助金额:
    $ 54.17万
  • 项目类别:
Molecular and Cellular Mechanisms of IL-17 Signaling
IL-17 信号传导的分子和细胞机制
  • 批准号:
    8453438
  • 财政年份:
    2011
  • 资助金额:
    $ 54.17万
  • 项目类别:

相似国自然基金

时空序列驱动的神经形态视觉目标识别算法研究
  • 批准号:
    61906126
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
  • 批准号:
    41901325
  • 批准年份:
    2019
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
  • 批准号:
    61802133
  • 批准年份:
    2018
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
  • 批准号:
    61872252
  • 批准年份:
    2018
  • 资助金额:
    64.0 万元
  • 项目类别:
    面上项目
针对内存攻击对象的内存安全防御技术研究
  • 批准号:
    61802432
  • 批准年份:
    2018
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Identifying and targeting a novel mechanism of chemotherapy-induced immunotherapeutic resistance in non-small cell lung cancer
识别和靶向非小细胞肺癌化疗引起的免疫治疗耐药的新机制
  • 批准号:
    10657188
  • 财政年份:
    2023
  • 资助金额:
    $ 54.17万
  • 项目类别:
Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation
通过调节肿瘤炎症提高胶质瘤免疫治疗效果
  • 批准号:
    10750788
  • 财政年份:
    2023
  • 资助金额:
    $ 54.17万
  • 项目类别:
Investigating cerebrovascular dysfunction and cerebral atrophy in severe traumatic brain injury
严重颅脑损伤中脑血管功能障碍和脑萎缩的调查
  • 批准号:
    10742569
  • 财政年份:
    2023
  • 资助金额:
    $ 54.17万
  • 项目类别:
Microvascular Neuroimaging in Age-related Alzheimer's Disease and Tauopathies
年龄相关性阿尔茨海默病和 Tau蛋白病的微血管神经影像学
  • 批准号:
    10738372
  • 财政年份:
    2023
  • 资助金额:
    $ 54.17万
  • 项目类别:
Defining the role of CNPY2 in promoting tumor progression through mediation of macrophage.
定义 CNPY2 通过巨噬细胞介导促进肿瘤进展的作用。
  • 批准号:
    10657859
  • 财政年份:
    2023
  • 资助金额:
    $ 54.17万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了